Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Reporting contributes to national pharmacovigilance and helps build the evidence base for emerging treatments
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial
Among these patients, 982 were treated by applying GLP-1RAs or DPP-4 inhibitors, while 2,769 received other antidiabetic medications
And yes, rapid urbanization, plus evolving lifestyle patterns, are also pushing demand up across the region
However, these drugs are not devoid of side effects, necessitating careful consideration and medical guidance for their usage
US$ 20.75
US$ 29.13
US$ 21.88
US$ 25.56
US$ 20.68
US$ 27.21
